Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.59 |
| ▸ | JAK1 | P23458 | 2/20 | 0.59 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 6/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26686499 | 0.97 | TYK2 (0.59) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL22659338 | 0.94 | ACVRL1 (0.66) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL23893005 | 0.81 | ABL1 (0.56) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL16914215 | 0.81 | TYK2 (0.62) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL16703133 | 0.80 | MAPT (0.59) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL22187902 | 0.79 | TYK2 (0.53) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL13922555 | 0.78 | SMN1; SMN2 (0.61) | TYK2JAK2ACVRL1GSK3BMAPT | |
| SCHEMBL15350271 | 0.78 | TYK2 (0.57) | TYK2JAK2JAK1ACVRL1GSK3B | |
| SCHEMBL13922554 | 0.77 | SMN1; SMN2 (0.64) | TYK2JAK2ACVRL1GSK3B | |
| SCHEMBL16702421 | 0.77 | GSK3B (0.59) | TYK2JAK2JAK1ACVRL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | TYK2 757/4885JAK2 207/4885JAK1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.